Who
Ankur Dhingra
SVP, Chief Financial Officer
Company insider
Files Form 4 as: SVP, Chief Financial Officer, Illumina; Chief Financial Officer, Summit Therapeutics; Chief Financial Officer, CareDx.
In numbers
- Trades disclosed
- 28
- Buys
- 7
- Sells
- 0
- Bought
- $1.4M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 25 Mar 2021
- Last trade
- 5 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Mar 2026filed 9 Mar 2026 | ILMN IlluminaLife-science tools | SEC FORM 4 Code A | $1.2M9,358 at $128.24 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ILMN Illuminaoption or derivative · Life-science tools | SEC FORM 4 Code A | $1.4M10,918 at $128.24 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ILMN Illuminaoption or derivative · Life-science tools | SEC FORM 4 Code A | $1.4M10,918 at $128.24 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ILMN Illuminaoption or derivative · Life-science tools | SEC FORM 4 Code A | $1.4M10,918 at $128.24 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ILMN Illuminaoption or derivative · Life-science tools | SEC FORM 4 Code A | $1.4M10,918 at $128.24 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ILMN IlluminaLife-science tools | SEC FORM 4 Code A | $1.2M9,358 at $128.24 | filing |
| 12 May 2025filed 14 May 2025 | ILMN IlluminaLife-science tools | SEC FORM 4 Bought | $495K6,100 at $81.21 | filing |
| 5 Mar 2025filed 7 Mar 2025 | ILMN Illuminaoption or derivative · Life-science tools | SEC FORM 4 Code A | —11,437 at $0.00 | filing |
| 5 Mar 2025filed 7 Mar 2025 | ILMN Illuminaoption or derivative · Life-science tools | SEC FORM 4 Code A | —11,437 at $0.00 | filing |
| 5 Mar 2025filed 7 Mar 2025 | ILMN IlluminaLife-science tools | SEC FORM 4 Code A | —9,803 at $0.00 | filing |
| 6 May 2024filed 8 May 2024 | ILMN Illuminaoption or derivative · Life-science tools | SEC FORM 4 Code A | —10,296 at $0.00 | filing |
| 6 May 2024filed 8 May 2024 | ILMN Illuminaoption or derivative · Life-science tools | SEC FORM 4 Code A | —10,296 at $0.00 | filing |
| 6 May 2024filed 8 May 2024 | ILMN IlluminaLife-science tools | SEC FORM 4 Code A | —8,826 at $0.00 | filing |
| 26 Mar 2024filed 27 Mar 2024 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $375K100,000 at $3.75 | filing |
| 13 Dec 2023filed 13 Dec 2023 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,505700 at $2.15 | filing |
| 13 Dec 2023filed 13 Dec 2023 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $43K19,700 at $2.17 | filing |
| 7 Mar 2023filed 8 Mar 2023 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $206K196,362 at $1.05 | filing |
| 16 Aug 2022filed 8 Mar 2023 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $13K13,027 at $0.97 | filing |
| 16 Aug 2022filed 8 Mar 2023 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K24,658 at $0.97 | filing |
| 16 Aug 2022filed 17 Aug 2022 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K11,557 at $0.97 | filing |
News
Illumina's (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?ILMN · insidermonkey.com · 13 Oct 2026Analyzing CollPlant Biotechnologies (NASDAQ:CLGN) and CareDx (NASDAQ:CDNA)CDNA · themarketsdaily.com · 10 Oct 2026Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysILMN · themarketsdaily.com · 7 Oct 2026
0 headlines in the last 90 days name Ankur Dhingra; 3 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.